Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosisMarco Merli, Hamid Hasson, Laura Galli et al.|Journal of Antimicrobial Chemotherapy|2016Cited by 8
Multiclass hepatitis C virus resistance to direct acting antivirals in real life interferon-free regimens failures advocates for tailored second-line therapiesVelia Chiara Di Maio, M. Paoloni, Valeria Cento et al.|Journal of Hepatology|2017Cited by 2
Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohortsRoberto Rossotti, Antonella d’Arminio Monforte, Antonella Cingolani et al.|Digestive and Liver Disease|2020Cited by 2
Multiclass HCV resistance to interferon-free direct acting antivirals regimens in real life failures advocates for tailored second-line therapiesVelia Chiara Di Maio, Valeria Pace Palitti, Valeria Cento et al.|Digestive and Liver Disease|2017Cited by 1
Pharmacokinetics of simeprevir and risk of skin reactions in patients with co-infection HIV/HCV with or without a protease inhibitor containing HAARTLetizia Marinaro, Stefano Bonora, Ambra Barco et al.|Unknown|2016Cited by 0